Heart Failure pp 183-195 | Cite as

Role of Adenosine in Cardioprotection

  • Masafumi Kitakaze
  • Tetsuo Minamino
  • Koichi Node
  • Seiji Takashima
  • Hiroharu Funaya
  • Tsunehiko Kuzuya
  • Masatsugu Hori


Adenosine may act as an endogenous cardioprotective substance in pathophysiological conditions of the heart, such as myocardial ischemia and heart failure. For example, when brief periods of ischemia precede sustained ischemia, infarct size is markedly limited, a phenomenon known as ischemic preconditioning. Because exogenous adenosine limits infarct size markedly, we tested whether endogenous adenosine is involved in the mediation of the infarct size-limiting effect of ischemic preconditioning. In the open-chest dog model, we found that ischemic preconditioning activates the enzyme responsible for adenosine release, i.e., ecto-5′-nucleotidase. Furthermore, the inhibitor of ecto-5′-nucleotidase blunted the infarct size-limiting effect of ischemic preconditioning, which establishes the cause-effect relationship between activation of ecto-5′-nucleotidase and the infarct size-limiting effect. We also found that activation of protein kinase C was responsible for this activation of ecto-5′nucleotiase. On the other hand, we found that plasma adenosine levels were increased in patients with chronic heart failure. Ecto-5′-nucleotidase activity was increased in blood and myocardium in patients with chronic heart failure, which may be responsible for the increases in adenosine levels in plasma and the myocardium. Furthermore, we found that further elevation of plasma adenosine levels caused by either dipyridamole or dilazep improves the severity of chronic heart failure. Taken together, we propose potential mechanisms for cardioprotection attributable to adenosine in pathophysiological states in heart diseases. The establishment of adenosine therapy may throw light on the new paradigm for the treatment of either ischemic heart diseases or chronic heart failure.

Key words

Infarct size Preconditioning Adenosine PKC Heart failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hori M, Kitakaze M (1991) Adenosine, the heart and coronary circulation (brief review). Hypertension 18: 565–574PubMedGoogle Scholar
  2. 2.
    Kitakaze M, Hori M, Kamada T (1993) The role of adenosine and its interaction with alpha-adrenoceptor activity in myocardial ischemic and reperfusion injury (brief review). Cardiovasc Res 27: 18–27PubMedCrossRefGoogle Scholar
  3. 3.
    Lagerkranser N, Sollevi A, Irestedt L, Tidgren B, Andreen M (1985) Renin release during controlled hypotension with sodium nitroprusside, nitroglycerin and adenosine: a comparative study in the dogs. Acta Anaesthesiol Scand 29: 45–49PubMedCrossRefGoogle Scholar
  4. 4.
    Parmely MJ, Zhou WW, Edward CK III, Borcherding DR, Silverstein R, Morrison DC (1993) Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrotic factor-a production and protect mice against endotoxin challenge. J Immunol 151: 389–396PubMedGoogle Scholar
  5. 5.
    Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136PubMedCrossRefGoogle Scholar
  6. 6.
    Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM (1991) Protection against infarction afforded by preconditioning is mediated by A, adenosine receptors in rabbit heart. Circulation 84: 350–356PubMedGoogle Scholar
  7. 7.
    Thornton JD, Liu GS, Olsson RA, Downey JM (1992) Intravenous pretreatment with A1-selective adenosine analogue protects the heart against infarction. Circulation 85: 659–665PubMedGoogle Scholar
  8. 8.
    Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O (1992) Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 86: 979–985PubMedGoogle Scholar
  9. 9.
    Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R (1987) Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76: 1135–1145PubMedCrossRefGoogle Scholar
  10. 10.
    Packer M (1988) Neurohumoral interactions and adaptation in congestive heart failure. Circulation 77: 721–730PubMedCrossRefGoogle Scholar
  11. 11.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin E (1975) Effects of chronic ß-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022–1036PubMedCrossRefGoogle Scholar
  12. 12.
    The SOLVD Investigations (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691CrossRefGoogle Scholar
  13. 13.
    Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72: 561–566PubMedCrossRefGoogle Scholar
  14. 14.
    Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T (1993) Ischemic preconditioning increases adenosine release and 5’-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implication for myocardial salvage. Circulation 87: 208–215PubMedGoogle Scholar
  15. 15.
    Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T (1994) The infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5’-nucleotidase activity and attenuation of adenosine release. Circulation 89: 1237–1246PubMedGoogle Scholar
  16. 16.
    Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T (1996) The role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5’-nucleotidase. Circulation 93: 781–791PubMedGoogle Scholar
  17. 17.
    Kitakaze M, Hod M, Morioka T, Minamino T, Takashima S. Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T (1994) Alpha,-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5’-nucleotidase activity. J Clin Invest 93: 2197–2205Google Scholar
  18. 18.
    Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hon M (1997) Plasma adenosine levels increase in patients with chronic heart failure. Circulation 95: 1363–1365PubMedGoogle Scholar
  19. 19.
    Kitakaze M, Funaya H, Minamino T, Node K, Koretsune Y. Komamura K, Sato H, Hori M (1998) A new strategy for the treatment of chronic heart failure: elevation of plasma adenosine levels. Cardiovas Drug Ther 12: 307–309Google Scholar
  20. 20.
    Van Wylen DGL (1994) Effects of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia Circulation 89: 2283–2289Google Scholar
  21. 21.
    Al-Awqati Q (1995) Regulation of ion channels by ABC transporter that secrete ATP. Science 269: 805–806PubMedCrossRefGoogle Scholar
  22. 22.
    Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD, Harken AH (1993) Preconditioning against myocardial dysfunction after ischemia and reperfusion by a-adrenergic mechanism. Circ Res 73: 656–670PubMedGoogle Scholar
  23. 23.
    Kitakaze M, Minamino T, Node K, Komamura K, Inoue M, Hori M, Kamada T (1996) Activation of ecto-5’-nucleotidase by protein kinase C attenuates irreversible cellular injury due to hypoxia and reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 28: 1945–1955PubMedCrossRefGoogle Scholar
  24. 24.
    Kitakaze M, Hon M, Morioka T, Minamino T, Takashima S, Okazaki Y, Node K, Komamura K, Iwakura K, Inoue M, Kamada T (1995) a,-Adrenoceptor activation increases ectosolic 5’-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation 91:2226–2234PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2000

Authors and Affiliations

  • Masafumi Kitakaze
    • 1
  • Tetsuo Minamino
    • 1
  • Koichi Node
    • 1
  • Seiji Takashima
    • 1
  • Hiroharu Funaya
    • 1
  • Tsunehiko Kuzuya
    • 1
  • Masatsugu Hori
    • 1
  1. 1.First Department of MedicineOsaka University School of MedicineSuitaJapan

Personalised recommendations